Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of misleading statements regarding its product SLK and its comparison to BIMZELX, which led to significant stock price decline following disappointing clinical trial results [2][4][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake to contact them for discussing legal options [1]. - The firm is investigating claims against MoonLake and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the efficacy of SLK compared to BIMZELX [4]. Group 2: Financial Impact - On September 28, 2025, MoonLake announced that SLK failed to demonstrate competitive efficacy relative to BIMZELX, resulting in a stock price drop of $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [5]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities litigation [3]. Group 3: Company Background - MoonLake Immunotherapeutics is listed on NASDAQ under the ticker MLTX [2]. - The company is involved in the development of therapeutics, specifically focusing on Nanobodies and their clinical applications [4].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from clinical trials that raised questions about the company's drug's regulatory approval and commercial viability [1][2][5]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically through its investigational therapeutic sonelokimab (SLK) [3]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation from competitors [4]. Group 3: Clinical Trial Results - The VELA Phase 3 trials for sonelokimab reported disappointing results, with VELA-2 failing to meet its primary endpoint, which raised concerns about the drug's chances for regulatory approval [6]. - Following the announcement of the trial results on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][3][4]. Summary by Sections Lawsuit Details - The lawsuit claims that MoonLake's assertions regarding the superiority of its Nanobody technology were misleading, particularly in comparison to the FDA-approved competitor BIMZELX [3]. - The stock price plummeted from $61.99 to $6.24, representing a 90% loss, after the VELA-2 trial failed to meet its primary endpoint and demonstrated inferior efficacy [4]. Timeline and Key Information - Class Period: March 10, 2024 – September 29, 2025 - Lead Plaintiff Deadline: December 15, 2025 - Significant Stock Drop: 90% loss on September 29, 2025, due to failed trial results [4]. Next Steps for Investors - Investors who purchased MoonLake stock during the specified class period and incurred substantial losses are encouraged to contact Hagens Berman to explore legal options and potential appointment as Lead Plaintiff [5]. About Hagens Berman - Hagens Berman is a global plaintiffs' rights firm that focuses on corporate accountability and has secured over $2.9 billion for clients in similar cases [7].

Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab (SLK) [8] - The lawsuit claims that MoonLake promoted SLK as superior to competing drugs while failing to disclose its lack of proven superiority [8] - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price dropped nearly 90%, resulting in significant investor losses [8] Allegation Details - The lawsuit covers all individuals and entities who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [8] - The complaint highlights that MoonLake's executives touted SLK's unique clinical advantages without revealing that it targeted the same molecules as UCB's BIMZELX [8] - The stock plummeted 89.9% on September 29, 2025, after the company disclosed that the VELA-2 trial did not achieve statistical significance due to unexpected events in the placebo group [8] Next Steps - Investors who suffered losses and wish to participate in the lawsuit must apply to the Court by December 15, 2025, to be appointed as lead plaintiff [8] - Interested parties can contact Bragar Eagel & Squire, P.C. for more information regarding their rights and the claims [4][5]

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically targeting moderate to severe hidradenitis suppurativa with its investigational drug sonelokimab [3]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a higher clinical response for patients, suggesting a competitive advantage over traditional monoclonal antibody treatments [4]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Points - The Law Offices of Frank R. Cruz is reminding investors about the December 15, 2025 deadline to participate as a lead plaintiff in a securities fraud class action lawsuit against MoonLake Immunotherapeutics [1] Group 1 - The lawsuit is on behalf of investors who acquired MoonLake securities between March 10, 2024, and September 29, 2025, inclusive [1]

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the December 15, 2025 deadline for a securities class action [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions, highlighting their own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its success in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of MoonLake's Nanobodies compared to traditional monoclonal antibodies, leading to investor losses when the truth was revealed [5].

Core Viewpoint - A securities class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][4]. Company Allegations - The lawsuit centers on claims that MoonLake misled investors regarding the superiority of its Nanobody technology compared to conventional monoclonal antibodies, particularly against the FDA-approved competitor BIMZELX [3]. - The specific event that triggered the stock drop was the failure of the VELA-2 trial to meet its primary endpoint, revealing that the drug's efficacy was inferior to that of its competitor [4]. Financial Impact - MoonLake's stock price plummeted from $61.99 to $6.24, representing a 90% loss on September 29, 2025, after the trial results were announced [4]. Investor Guidance - Investors who purchased MoonLake stock between March 10, 2024, and September 29, 2025, and experienced significant losses are encouraged to contact Hagens Berman to explore their legal options and potential appointment as Lead Plaintiff [5].

Core Viewpoint - The complaint against MoonLake alleges violations of federal securities laws due to false and misleading statements regarding the efficacy and structure of its drug SLK compared to monoclonal antibodies like BIMZELX [2]. Group 1: Allegations and Legal Proceedings - The complaint claims that MoonLake and its executives failed to disclose that SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [2]. - It is alleged that SLK's unique Nanobody structure does not provide a clinical benefit over BIMZELX's traditional monoclonal structure [2]. - The complaint also states that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for positive statements about SLK's superiority [2]. Group 2: Market Reaction - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price dropped by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique structure does not provide superior clinical benefits [2]. - It is alleged that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for the positive claims made about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4].